drugset / Trial / NCT05519059
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This ia a multicenter, Single-Arm, Open-Label Phase I Clinical Study Evaluating the Safety and Tolerability of Pelareorep Combined with Paclitaxel Injection and the Intracorporal Process of Pelareorep in Chinese Patients with Advanced or Metastatic Breast Cancer.
Timeline
- Start
- 2021-10-11
- Primary completion
- 2022-09-29
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelareorep | Other / unclassified | 1.5e+10 unknown | — |
| Subject | Pelareorep | Other / unclassified | 3e+10 unknown | — |
| Subject | Pelareorep | Other / unclassified | 4.5e+10 unknown | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |